Efficacy and Toxicity Assessment of Different Antibody Based Antiangiogenic Drugs by Computational Docking MethodReport as inadecuate

Efficacy and Toxicity Assessment of Different Antibody Based Antiangiogenic Drugs by Computational Docking Method - Download this document for free, or read online. Document in PDF available to download.

Advances in Bioinformatics - Volume 2016 2016, Article ID 7053712, 11 pages -

Research Article

Department of Physiology, West Bengal State University, Berunanpukuria, Malikapur, Barasat, Kolkata 700 126, India

Society for Systems Biology and Translational Research, No. 103, Block C, Bangur Avenue, Kolkata 700 055, India

Received 30 November 2015; Accepted 21 January 2016

Academic Editor: Huixiao Hong

Copyright © 2016 Sayan Mukherjee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Bevacizumab and trastuzumab are two antibody based antiangiogenic drugs that are in clinical practice for the treatment of different cancers. Presently applications of these drugs are based on the empirical choice of clinical experts that follow towards population based clinical trials and, hence, their molecular efficacies in terms of quantitative estimates are not being explored. Moreover, different clinical trials with these drugs showed different toxicity symptoms in patients. Here, using molecular docking study, we made an attempt to reveal the molecular rationale regarding their efficacy and off-target toxicity. Though our study reinforces their antiangiogenic potentiality and, among the two, trastuzumab has much higher efficacy; however, this study also reveals that compared to bevacizumab, trastuzumab has higher toxicity effect, specially on the cardiovascular system. This study also reveals the molecular rationale of ocular dysfunction by antiangiogenic drugs. The molecular rationale of toxicity as revealed in this study may help in the judicious choice as well as therapeutic scheduling of these drugs in different cancers.

Author: Sayan Mukherjee, Gopa Chatterjee, Moumita Ghosh, Bishwajit Das, and Durjoy Majumder

Source: https://www.hindawi.com/


Related documents